摘要
目的探讨重组人干扰素α2b阴道泡腾胶囊治疗宫颈人乳头瘤病毒(HPV)感染患者的临床效果。方法选取佛山市南海区妇幼保健院收治的300例宫颈HPV感染患者作为研究对象,按照随机抽签法分为观察组(n=150)和对照组(n=150)。对照组采用复方沙棘籽油栓治疗,观察组采用重组人干扰素α2b阴道泡腾胶囊治疗。比较两组患者的HPV转阴情况、治疗后HPV负荷量及不良反应发生情况。结果 3个疗程结束后,观察组患者HPV转阴率为82.00%(123/150),较对照组的16.00%(24/150)高(P<0.05);治疗后1个月两组患者HPV负荷量比较差异无统计学意义(P>0.05);观察组患者治疗后3个月、6个月HPV负荷量均较对照组低(均P<0.05);观察组不良反应发生率为8.00%(12/150),与对照组的10.00%(15/150)比较,差异无统计学意义(P>0.05)。结论采用重组人干扰素α2b阴道泡腾胶囊治疗宫颈HPV感染患者,能明显提高HPV转阴率,有效降低HPV负荷量,还能显著降低不良反应发生率。
Objective To explore the clinical effectS of recombinant human interferon α-2 b vaginal effervescent capsule in the treatment of cervical human papillomavirus infection. Methods A total of 300 cases of cervical HPV infection in Nanhai Maternal and Child Health Hospital of Foshan City were selected as the research object. They were divided into the observation group(n=150)and the control group(n=150) according to random sampling. The control group was treated with compound seabuckthorn seed oil suppository, and the observation group was treated with recombinant human interferon α-2 b vaginal effervescent capsule. HPV negative conversion, HPV load and adverse reactions after treatment were compared between the two groups. Results After the end of 3 courses’ treatment, the HPV negative rate was 82.00%(123/150) higher than the control group 16.00%(24/150)(P<0.05).After 1 month’s treatment, there was no significant difference in the comparsion of HPV laod of the two groups(P>0.05). At 3 months and 6 months after treamnt, the HPV load in the observation group was lower than the control group(P<0.05). There was no significant difference between the advser reaction rate of 8.00%(12/150) in the observation group and 10.00% in the control group of(15/150)(P>0.05). Conclusion Recombinant human interferon α-2 b vaginal effervescent capsule in patients with cervical HPV infection can significantly improve the HPV negative rate, can significantly improve the HPV negative rate, effectively reduce the HC2 value, can also significantly reduce the incidence of adverse reactions.
作者
黄广强
陈泳华
HUANG Guang-Qiang;CHEN Yong-Hua(Nanhai Maternal and Child Health Hospital,Foshan 528200,China)
出处
《中国药物经济学》
2019年第2期77-79,共3页
China Journal of Pharmaceutical Economics
